

GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103

Overview

2024/04/26 19:31:01

Price

61.17 EUR

Difference ▲ 0.74% (0.45)

General attributes

ISIN US3755581036

Symbol GILD

Exchange Duesseldorf

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 76,296 EUR

Benchmark S&P 500

Market data

Bid (Bid size) -

Ask (Ask size) -

Open 60.99 EUR

High 61.20 EUR

Low 60.81 EUR

Close (prev. day) 60.72 EUR

VWAP 56.15 EUR

Volume (pcs) 17

Trading volume 1,040.40

Number of trades 6

Last size 0

Futures and Options

Related Futures 15

Related Options -

PDF Downloads

Company report: GILEAD SCIENCES INC. 

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

| on instrument | on sector | on market | |
|---------------|---|-----------------------|---|
| Date | | Headline | Download |
| 2024/04/26 |  | Global Equity Ratings |  |
| 2024/04/03 |  | Global Equity Ratings |  |
| 2024/03/13 |  | Global Equity Ratings |  |
| 2024/02/22 |  | Global Equity Ratings |  |
| 2024/02/14 |  | Global Equity Ratings |  |

Details

2024/04/26 19:31:01

Price

61.17 EUR

Difference ▲ 0.74% (0.45)

General attributes

ISIN US3755581036

Symbol GILD

Exchange Duesseldorf

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 76,296 EUR

Benchmark S&P 500

Market data

Bid (Bid size) -

Ask (Ask size) -

Open 60.99 EUR

High 61.20 EUR

Low 60.81 EUR

Close (prev. day) 60.72 EUR

VWAP 56.15 EUR

Volume (pcs) 17

Trading volume 1,040.40

Number of trades 6

Last size 0

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|---------|---------|---------|
| Perf (%) | -17.72% | -19.00% | +12.98% |
| Perf (abs.) | -13.17 | -14.35 | +7.03 |
| Beta | 0.43 | 0.45 | 0.46 |
| Volatility | 25.42 | 22.39 | 22.78 |

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.) 62.03 EUR (3)

Ø price 30 days | Ø volume 30 days (pcs.) 64.95 EUR (1)

Ø price 100 days | Ø volume 100 days (pcs.) 69.80 EUR (4)

Ø price 250 days | Ø volume 250 days (pcs.) 70.67 EUR (5)

YTD High | date 80.04 EUR (2024/01/22)

YTD Low | date 60.72 EUR (2024/04/25)

52 Weeks High | date 80.04 EUR (2024/01/22)

52 Weeks Low | date 60.72 EUR (2024/04/25)

All listings for GILEAD SCIENCES INC.

| Exchange ⊕ | Date | Time | Price | Trading volume (mio.) | Number of trades |
|--|------------|-------|-----------|-----------------------|------------------|
| Xetra | 2024/04/26 | 17:35 | 61.33 EUR | 0.07 | 30 |
| Vienna Stock Exchange | 2024/04/26 | 17:32 | 61.42 EUR | 0.00 | 3 |
| Tradegate | 2024/04/26 | 22:26 | 61.14 EUR | 0.39 | 60 |
| Stuttgart | 2024/04/26 | 20:19 | 61.30 EUR | 0.02 | 7 |
| SIX Swiss Exchange | 2022/ | 17:36 | 79.50 CHF | 0.00 | 1 |

| | | | | | | | |
|---|----------------|-------|-----------|--------|--|--|---------|
| | 11/02 | | | | | | |
| SIX Swiss Exchange | 2020/ 04/17 | 17:35 | 85.00 USD | 0.00 | | | 1 |
| Nasdaq | 2024/ 04/26 | 22:00 | 65.42 USD | 811.39 | | | 107,440 |
| Munich | 2024/ 04/26 | 08:03 | 61.39 EUR | 0.00 | | | 2 |
| London Stock Exchange European Trade Reporting | 2024/ 04/26 | 17:30 | 65.47 USD | 0.00 | | | 4 |
| Hanover | 2024/ 04/26 | 08:58 | 60.97 EUR | 0.00 | | | 3 |
| Hamburg | 2024/ 04/26 | 08:05 | 61.19 EUR | 0.00 | | | 3 |
| Frankfurt | 2024/ 04/26 | 14:51 | 61.18 EUR | 0.03 | | | 6 |
| Euronext Milan MTF Trading After Hours | 2024/ 04/05 | 18:23 | 64.51 EUR | 0.00 | | | 1 |
| Euronext Milan MTF Global Equity Market | 2024/ 04/26 | 17:44 | 61.46 EUR | 0.03 | | | 6 |
| Duesseldorf | 2024/ 04/26 | 19:31 | 61.17 EUR | 0.00 | | | 6 |
| Berlin | 2024/ 04/26 | 08:08 | 61.10 EUR | 0.00 | | | 2 |

Company profile

Company Logo



Contact Details

GILEAD SCIENCES INC.

--

333 Lakeside Drive - 94404 Foster City

Telefon: +1-650-574-3000

Fax: +1-650-522-5853

E-mail: -

PDF Downloads

Company report: GILEAD SCIENCES INC. 

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Members of Management Board

| | |
|-----------------------|-------------------------------|
| Jacqueline Barton | Member of Board of Directors |
| Jeffrey Bluestone | Member of Board of Directors |
| Sandra Horning | Member of Board of Directors |
| Ted Love | Member of Board of Directors |
| Anthony Welters | Member of Board of Directors |
| Harish M. Manwani | Member of Board of Directors |
| Javier Rodriguez | Member of Board of Directors |
| Kelly Kramer | Member of Board of Directors |
| Kevin Lofton | Member of Board of Directors |
| Daniel O'Day | Chairman of Managing Board |
| Andrew Dickinson | Member of Executive Committee |
| Deborah H. Telman | Member of Executive Committee |
| Flavius Martin | Member of Executive Committee |
| Johanna Mercier | Member of Executive Committee |
| Jyoti Mehra | Member of Executive Committee |
| MD, PhD Merdad Parsey | Member of Executive Committee |
| Stacey Ma | Member of Executive Committee |